Skip to content

Investors Overview

Esperion is a pharmaceutical company passionately committed to developing and commercializing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid is being developed as a once-daily, oral inhibitor of ATP Citrate Lyase (ACL), and is designed to bring a targeted mechanism of action to address patients’ unmet medical needs.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third Quarter Over 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets in the U.S. CLEAR Outcomes Study Design Highlighted in The American
Toggle Summary Esperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021
ANN ARBOR, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2020 financial results after the close of the U.S. financial markets on Tuesday, February 23, 2021. Following the release, company management will host a webcast
Toggle Summary Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on January 28, 2021, the Compensation Committee of Esperion’s Board of Directors granted 10 new employees (i) non-qualified stock options to purchase an aggregate of 150,000 shares of its common stock,
Toggle Summary ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
– Fourth-quarter 2020 U.S. net product revenue estimated between $8.0 and $8.5 million – – Range represents over 140 percent sequential growth for NEXLETOL ® (bempedoic acid) tablets and NEXLIZET ® (bempedoic acid and ezetimibe) tablets – – Company provides full-year 2021 operating expense guidance
Toggle Summary Esperion to Present at the 39th Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Mich., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Tim M. Mayleben, will present at the virtual 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 7:30 a.m.